CALL FOR PAPERS

CERTIFICATE

IMPACT FACTOR 2019

Subject Area

  • Life Sciences / Biology
  • Architecture / Building Management
  • Asian Studies
  • Business & Management
  • Chemistry
  • Computer Science
  • Economics & Finance
  • Engineering / Acoustics
  • Environmental Science
  • Agricultural Sciences
  • Pharmaceutical Sciences
  • General Sciences
  • Materials Science
  • Mathematics
  • Medicine
  • Nanotechnology & Nanoscience
  • Nonlinear Science
  • Chaos & Dynamical Systems
  • Physics
  • Social Sciences & Humanities

Why Us? >>

  • Open Access
  • Peer Reviewed
  • Rapid Publication
  • Life time hosting
  • Free promotion service
  • Free indexing service
  • More citations
  • Search engine friendly

Plagiarism Detection

IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.

 

 

 

 

 

 

 

 

 

 

 

 

Serum high sensitivity c-reactive protein as a prognostic and therapeutic marker in advanced stage non-small cell lung cancer

Author: 
Arvind Lakesar
Subject Area: 
Health Sciences
Abstract: 

Introduction: CRP is shown to be elevated in many malignancies including lung cancer. In patients of NSCLC, elevated CRP levels prior to therapy are related with bad prognosis. Studies have shown that high CRP is also related to advanced stages. CRP level is much higher in malignancy cases than only inflammatory condition like COPD. In cancer, CRP is possibly increased by tissue inflammation and cytokines released by tumor cells indicating a higher tumor burden. Objective: This study was designed to evaluate serum mean hs-CRP levels in advanced stage NSCLC at diagnosis, after every 2 cycles of chemotherapy and to correlate this with treatment response. Baseline hs-CRP with correlated with tumor stage and T size and also compared with baseline levels in patients of COPD and healthy controls. Material and Methods: This Hospital based observational study included 20 newly diagnosed patients of NSCLC (stage IIIB and IV) in good PS, 20 patients of stable COPD and 20 healthy controls. Baseline hs-CRP values were compared among three groups. NSCLC cases were assessed for baseline hs-CRP, tumor size, subtypes, staging and treatment response. After every 2 cycles of chemotherapy, parameters were reassessed and compared. hs-CRP was tested by routine clinical lab test protocols using instrument Labmate and tumor response was assessed using the RECIST 1.1 criteria. Results: Baseline mean hs-CRP values of NSCLC, COPD, controls were 28.11±16.02 mg/L, 8.59±3.53 mg/L,0.60±0.30 mg/L respectively (p<0.001). Squamous Cell Carcinoma (SCC) had significantly higher CRP as compared to adenocarcinoma, and NSCLC-NOS. No statistical significance was found between SCC and large cell ca. After treatment, 15% had CR, 35% had PR, 25% had SD and 25% had PD. Baseline mean hs-CRP values in patients with CR, PR, SD and PD groups were 8.13±.80 mg/L,19.27±2.99 mg/L,29.60±6.2 mg/L and 50.98±8.6 mg/L (p<0.001).This statistical significant difference was also noted post 2nd, 4th & 6th cycle of chemotherapy. Significant difference was noted in baseline mean tumor size and mean baseline hs-CRP (cut off 7cm). Strong correlation was found in change in mean tumor size and mean hs-CRP during treatment in all treatment response groups(r > 0.8). Conclusion: Despite the small number of patients in our study, we conclude the following. A high CRP value could suggest an occult lung cancer in patients of COPD. Higher stages at diagnosis have high level of CRP. Patients with high baseline tumor size have high level of baseline CRP. During treatment change in hs-CRP and change in tumor size have strong correlation. Patients having high baseline hs-CRP level are less likely to respond to chemotherapy and have progressive disease. hs-CRP might be useful for monitoring treatment response in Ca lung.

PDF file: 

IJMCE RECOMMENDATION

ONLINE PAYPAL PAYMENT

CURRENT ISSUE

NEWS

CHIEF EDITOR
Rosane Cavalcante Fragoso, Brasil
ASSOCIATE CHIEF EDITOR

   

Jean-Marc SABATIER
Chief Scientific Officer and Head of a Research Group
France

Advantages of IJCR

  • Rapid Publishing
  • Professional publishing practices
  • Indexing in leading database
  • High level of citation
  • High Qualitiy reader base
  • High level author suport

 

 

 

 

 

 

 

 

 

 

 

EDITORIAL BOARD

Luai Farhan Zghair
Iraq
Hasan Ali Abed Al-Zu’bi
Jordanian
Fredrick OJIJA
Tanzanian
Firuza M. Tursunkhodjaeva
Uzbekistan
Faraz Ahmed Farooqi
Saudi Arabia
Eric Randy Reyes Politud
Philippines
Elsadig Gasoom FadelAlla Elbashir
Sudan
Eapen, Asha Sarah
United State
Dr.Arun Kumar A
India
Dr. Zafar Iqbal
Pakistan
Dr. SHAHERA S.PATEL
India
Dr. Ruchika Khanna
India
Dr. Recep TAS
Turkey
Dr. Rasha Ali Eldeeb
Egypt
Dr. Pralhad Kanhaiyalal Rahangdale
India
DR. PATRICK D. CERNA
Philippines
Dr. Nicolas Padilla- Raygoza
Mexico
Dr. Mustafa Y. G. Younis
Libiya
Dr. Muhammad shoaib Ahmedani
Saudi Arabia
DR. MUHAMMAD ISMAIL MOHMAND
United State
DR. MAHESH SHIVAJI CHAVAN
India
DR. M. ARUNA
India
Dr. Lim Gee Nee
Malaysia
Dr. Jatinder Pal Singh Chawla
India
DR. IRAM BOKHARI
Pakistan
Dr. FARHAT NAZ RAHMAN
Pakistan
Dr. Devendra kumar Gupta
India
Dr. ASHWANI KUMAR DUBEY
India
Dr. Ali Seidi
Iran
Dr. Achmad Choerudin
Indonesia
Dr Ashok Kumar Verma
India
Thi Mong Diep NGUYEN
France
Dr. Muhammad Akram
Pakistan
Dr. Imran Azad
Oman
Dr. Meenakshi Malik
India
Aseel Hadi Hamzah
Iraq
Anam Bhatti
Malaysia
Md. Amir Hossain
Bangladesh
Ahmet İPEKÇİ
Turkey
Mirzadi Gohari
Iran